Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / INCY - Incyte Maruho ink deal for exclusive commercialization of ruxolitinib cream in Japan

INCY - Incyte Maruho ink deal for exclusive commercialization of ruxolitinib cream in Japan

Incyte Corporation
Incyte (NASDAQ:INCY) and Maruho on Thursday announced a deal for exclusive commercialization of ruxolitinib cream to treat autoimmune and inflammatory dermatology indications in Japan. This is a novel cream formulation of INCY's selective JAK2 inhibitor ruxolitinib. Maruho will make an upfront payment to Incyte and INCY will receive additional potential development, regulatory and commercial milestones and royalties on net sales of the product in Japan. Maruho will have the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases in Japan.

For further details see:

Incyte, Maruho ink deal for exclusive commercialization of ruxolitinib cream in Japan
Stock Information
Company Name: Incyte Corporation
Stock Symbol: INCY
Market: NASDAQ
Website: incyte.com
Menu
INCY INCY Quote INCY Short INCY News INCY Articles INCY Message Board
Get INCY Alerts

News, Short Squeeze, Breakout and More Instantly...